Potential biologicals for treatment of severe paediatric asthma
| Biological | Mode of action | Licensing status (UK) | Indications |
| Omalizumab | Binds IgE preventing binding to the high-affinity IgE receptor (FceRI) on mast cells and basophils May also have antiviral effects | Age 6 years and over | IgE between 30 and 1300 IU·mL−1 (In the UK) ≥4 prednisolone bursts per year, aeroallergen sensitised, adherent to standard therapy Dose depends on weight and IgE levels |
| Mepolizumab | Binds circulating IL-5 | Age 6 years and over | Blood eosinophils ≥150 cells per μL (In the UK) ≥4 prednisolone bursts per year, aeroallergen sensitised, adherent to standard therapy |
| Reslizumab | Binds circulating IL-5 | Not licensed | Not applicable |
| Benralizumab | Binds IL-5 receptor | Not licensed | Not applicable |
| Dupilumab | Binds IL-4/IL-13 receptor | Age 12 years and over | Only licensed for atopic eczema |